Association between changes in sleep quality and serum pro-inflammatory cytokine levels in patients with major depressive disorder following duloxetine treatment
Randomized trial investigates sleep quality and pro-inflammatory cytokines in MDD patients after duloxetine treatment, suggesting a link between sleep improvements and inflammation.
Key Points
The study aims to assess the impact of duloxetine treatment on sleep quality and pro-inflammatory cytokine levels in major depressive disorder patients.
Included 74 patients with MDD based on DSM-5 criteria administered duloxetine for 4 weeks.
Evaluated sleep parameters using polysomnography and measured pro-inflammatory cytokines via enzyme-linked immunosorbent assay.
Analyses included paired t-tests or Wilcoxon signed-rank tests, along with correlation analyses for associations between sleep and cytokine levels.
Significant increases in total sleep time and sleep efficiency, with decreases in wake time after sleep onset (all P < 0.001).
Serum levels of IL-1β, IL-8, IL-12, and IFN-γ were significantly reduced post-treatment (all P < 0.001).
Negative correlations observed between various sleep parameters and pro-inflammatory cytokine levels at baseline and following treatment.